Search

Displaying results 5681 - 5690 of 9132 in total
  1. Drug

    Oxepinac

    go.drugbank.com/drugs/DB21073
    Experimental

    Oxepinac is a small molecule drug. The usage of the INN stem '-ac' in the name indicates that Oxepinac is a anti-inflammatory agent, ibufenac derivative. … Oxepinac has a monoisotopic molecular weight of 268.07 Da.

  2. Drug

    Bufezolac

    go.drugbank.com/drugs/DB21081
    Experimental

    Bufezolac is a small molecule drug. The usage of the INN stem '-ac' in the name indicates that Bufezolac is a anti-inflammatory agent, ibufenac derivative. … Bufezolac has a monoisotopic molecular weight of 334.17 Da.

  3. Drug

    Mofezolac

    go.drugbank.com/drugs/DB21153
    Experimental

    Mofezolac is a small molecule drug. The usage of the INN stem '-ac' in the name indicates that Mofezolac is a anti-inflammatory agent, ibufenac derivative. … Mofezolac has a monoisotopic molecular weight of 339.11 Da.

  4. Drug

    Trifezolac

    go.drugbank.com/drugs/DB21380
    Experimental

    Trifezolac is a small molecule drug. The usage of the INN stem '-ac' in the name indicates that Trifezolac is a anti-inflammatory agent, ibufenac derivative. … Trifezolac has a monoisotopic molecular weight of 354.14 Da.

  5. Drug

    Tylosin

    go.drugbank.com/drugs/DB11475
    ExperimentalVet approved

    It has a broad spectrum of activity against Gram-positive organisms and a limited range of Gram-negative organisms. Tylosin is produced as a fermentation product of Streptomyces fradiae. … Tylosin is a bacteriostatic macrolide antibiotic and feed additive used in veterinary medicine.

    Synonyms: Tylosin A
  6. Drug

    Dabocemagene autoficel

    go.drugbank.com/drugs/DB17878
    Investigational

    Dabocemagene autoficel is an _ex vivo_, autologous cell-based gene therapy. It comprises autologous dermal fibroblasts genetically modified to express functional type VII collagen.

    Synonyms: THE CONTROL OF A HUMAN CYTOMEGALOVIRUS (CMV) PROMO, AUTOLOGOUS HUMAN DERMAL FIBROBLAST CELLS DERIVED FROM SKIN BIOPSIES, AND TRANSDUCED WITH A NON-REPLICATING, SELF-INACTIVATING LENTIVIRUS VECTOR THAT ENCODES HUMAN COLLAGEN TYPE VII ALPHA 1 (COL7A1) UNDER
  7. Drug

    Viralym-C

    go.drugbank.com/drugs/DB17975
    Investigational

    Viralym-C is an investigational T-cell immunotherapy developed by ViraCyte. It consists of Human Leukocyte Antigen (HLA)-matched cytomegalovirus (CMV)-specific T lymphocytes.

  8. Drug

    KAND567

    go.drugbank.com/drugs/DB16511
    Investigational

    Because COVID-19 involves cytotoxic cells associated with this pathway, KAND567 is currently being tested as a treatment for those with the illness[L32908]. … KAND567, a small molecule, blocks the fractaline (CX3CL1) receptor, which mediates the immune system response to inflammation[L32908].

  9. Drug

    Sirpiglenastat

    go.drugbank.com/drugs/DB17536
    Investigational

    Sirpiglenastat, also known as DRP-104, is a prodrug of [6-diazo-5-oxo-L-norleucine] (DON), which is a broad-acting glutamine antagonist.

  10. Drug

    RGX-501

    go.drugbank.com/drugs/DB17639
    Investigational

    RGX-501 is an adeno-associated virus vector 8 (AAV8)-mediated gene therapy that delivers a functional copy of the human low-density lipoprotein receptor (LDLR) gene to liver cells.